NYSEHealth CareHealth Care EquipmentS&P SmallCap 600
$27.16
-1.46 (-5.10%)
Close of Nov 06, 2026 · end-of-day data
ENOV 8-K filings in 2024
Every material Form 8-K Enovis filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Enovis reported third-quarter 2024 net sales of $505 million, up 21% on a reported basis, and a net loss from continuing operations of $34 million, or $0.61 per share, compared with a $0.36 loss a year earlier. Adjusted earnings per diluted share rose to $0.73 from $0.56, and the company raised its full-year adjusted EPS guidance to $2.75-$2.80, while narrowing its revenue and adjusted EBITDA expectations.
Q3 net sales of $505 million grew 21% reported and 6% on a comparable basis; Reconstructive sales rose 57% reported.
Q3 net loss from continuing operations was $34 million, or $0.61 per share; adjusted EPS was $0.73, up 30% year over year.
Full-year 2024 adjusted EPS guidance raised from $2.62-$2.77 to $2.75-$2.80.
Full-year revenue is estimated at $2.10 billion and adjusted EBITDA at $373-$378 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Enovis filing is on SEC EDGAR ↗. 8-K briefs of other companies →